{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-112949","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.003809+00:00","generated_at":"2026-05-17T08:20:29.980621+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026","bullets":["Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.","Timelines for all other pipeline programs remain unchanged.","Updated corporate presentation posted to company website; no other changes disclosed in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-112949","json":"https://secwatch.observer/filing/0000950170-25-112949.json","markdown":"https://secwatch.observer/filing/0000950170-25-112949.md","text":"https://secwatch.observer/filing/0000950170-25-112949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/0000950170-25-112949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/cgem-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:20:29.980621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}